Alcohol Cue-Induced Ventral Striatum Activity Predicts Subsequent Alcohol Self-Administration.


Journal

Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242

Informations de publication

Date de publication:
06 2020
Historique:
received: 01 01 2020
revised: 07 04 2020
accepted: 08 04 2020
pubmed: 15 5 2020
medline: 15 12 2021
entrez: 15 5 2020
Statut: ppublish

Résumé

Human laboratory paradigms are a pillar in medication development for alcohol use disorders (AUD). Neuroimaging paradigms, in which individuals are exposed to cues that elicit neural correlates of alcohol craving (e.g., mesocorticolimbic activation), are increasingly utilized to test the effects of AUD medications. Elucidation of the translational effects of these neuroimaging paradigms on human laboratory paradigms, such as self-administration, is warranted. The current study is a secondary analysis examining whether alcohol cue-induced activation in the ventral striatum is predictive of subsequent alcohol self-administration in the laboratory. Non-treatment-seeking heavy drinkers of East Asian descent (n = 41) completed a randomized, placebo-controlled, double-blind, crossover experiment on the effects of naltrexone on neuroimaging and human laboratory paradigms. Participants completed 5 days of study medication (or placebo); on day 4, they completed a neuroimaging alcohol taste cue-reactivity task. On the following day (day 5), participants completed a 60-minute alcohol self-administration paradigm. Multilevel Cox regressions indicated a significant effect of taste cue-elicited ventral striatum activation on latency to first drink, Wald χ Neuroimaging alcohol taste cue paradigms may be predictive of laboratory paradigms such as self-administration. Elucidation of the relationships among different paradigms will inform how these paradigms may be used synergistically in experimental medicine and medication development.

Sections du résumé

BACKGROUND
Human laboratory paradigms are a pillar in medication development for alcohol use disorders (AUD). Neuroimaging paradigms, in which individuals are exposed to cues that elicit neural correlates of alcohol craving (e.g., mesocorticolimbic activation), are increasingly utilized to test the effects of AUD medications. Elucidation of the translational effects of these neuroimaging paradigms on human laboratory paradigms, such as self-administration, is warranted. The current study is a secondary analysis examining whether alcohol cue-induced activation in the ventral striatum is predictive of subsequent alcohol self-administration in the laboratory.
METHODS
Non-treatment-seeking heavy drinkers of East Asian descent (n = 41) completed a randomized, placebo-controlled, double-blind, crossover experiment on the effects of naltrexone on neuroimaging and human laboratory paradigms. Participants completed 5 days of study medication (or placebo); on day 4, they completed a neuroimaging alcohol taste cue-reactivity task. On the following day (day 5), participants completed a 60-minute alcohol self-administration paradigm.
RESULTS
Multilevel Cox regressions indicated a significant effect of taste cue-elicited ventral striatum activation on latency to first drink, Wald χ
CONCLUSIONS
Neuroimaging alcohol taste cue paradigms may be predictive of laboratory paradigms such as self-administration. Elucidation of the relationships among different paradigms will inform how these paradigms may be used synergistically in experimental medicine and medication development.

Identifiants

pubmed: 32406553
doi: 10.1111/acer.14342
pmc: PMC7336863
mid: NIHMS1597505
doi:

Substances chimiques

Alcohol Deterrents 0
Central Nervous System Depressants 0
OPRM1 protein, human 0
Receptors, Opioid, mu 0
Ethanol 3K9958V90M
Naltrexone 5S6W795CQM
Aldehyde Dehydrogenase 1 Family EC 1.2.1
Aldehyde Dehydrogenase, Mitochondrial EC 1.2.1.3

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1224-1233

Subventions

Organisme : NCRR NIH HHS
ID : UL1 RR033176
Pays : United States
Organisme : NIAAA NIH HHS
ID : F32 AA027699
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA024635
Pays : United States
Organisme : UCLA Clinical and Translational Science Institute
ID : UL1RR033176
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR000124
Pays : United States
Organisme : NIAAA NIH HHS
ID : K24 AA025704
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA026190
Pays : United States
Organisme : UCLA Clinical and Translational Science Institute
ID : UL1TR000124
Pays : International
Organisme : NIAAA NIH HHS
ID : R01 AA021744
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01AA021744
Pays : United States

Informations de copyright

© 2020 by the Research Society on Alcoholism.

Références

Mol Psychiatry. 2016 Mar;21(3):348-56
pubmed: 26122584
Alcohol Clin Exp Res. 2014 Nov;38(11):2754-62
pubmed: 25421512
Methods Mol Biol. 2019;2011:195-219
pubmed: 31273701
BMC Med Genet. 2017 Oct 26;18(1):120
pubmed: 29070014
Addict Biol. 2020 Jan;25(1):e12717
pubmed: 30748046
Drug Alcohol Depend. 2012 Jun 1;123(1-3):1-6
pubmed: 22071118
Alcohol Clin Exp Res. 2008 Jul;32(7):1113-23
pubmed: 18540916
Arch Gen Psychiatry. 2012 Aug;69(8):842-52
pubmed: 22868938
Front Psychiatry. 2019 Sep 05;10:624
pubmed: 31543840
Alcohol Clin Exp Res. 2016 Jan;40(1):206-13
pubmed: 26727535
Curr Top Behav Neurosci. 2013;13:315-53
pubmed: 21792747
Alcohol Clin Exp Res. 2019 Oct;43(10):2038-2056
pubmed: 31386215
Sci Rep. 2017 May 23;7(1):2287
pubmed: 28536420
J Psychopharmacol. 2018 Jan;32(1):105-115
pubmed: 28892421
Am J Addict. 2017 Aug;26(5):516-525
pubmed: 28134463
Addict Biol. 2009 Jan;14(1):108-18
pubmed: 18855799
Biol Psychiatry. 2009 Jul 15;66(2):185-90
pubmed: 19249750
Neuropsychopharmacology. 2018 Aug;43(9):1891-1899
pubmed: 29802367
Alcohol Clin Exp Res. 2015 Aug;39(8):1312-27
pubmed: 26110981
Alcohol Clin Exp Res. 2018 Mar;42(3):613-623
pubmed: 29265379
Addict Biol. 2013 Jan;18(1):121-33
pubmed: 22574861
Behav Genet. 2016 Mar;46(2):151-69
pubmed: 26392368
Psychol Addict Behav. 2013 Jun;27(2):336-50
pubmed: 23586452
Psychopharmacol Bull. 1986;22(2):343-81
pubmed: 3774930
Addict Biol. 2017 Nov;22(6):1515-1527
pubmed: 27411969
Drug Alcohol Depend. 2019 Jul 1;200:181-190
pubmed: 31160146
Nat Commun. 2017 Dec 19;8(1):1983
pubmed: 29259158
Addict Biol. 2020 May;25(3):e12766
pubmed: 31066137
Psychopharmacology (Berl). 2006 Dec;189(2):201-10
pubmed: 17013640
J Neurosci Methods. 2015 Mar 15;242:58-64
pubmed: 25593047
Neuropsychopharmacology. 2018 Jun;43(7):1530-1538
pubmed: 29497164
Neuropsychopharmacology. 2011 Sep;36(10):2086-96
pubmed: 21677649
Front Psychiatry. 2017 Sep 25;8:182
pubmed: 28993741
Sci Adv. 2019 Sep 25;5(9):eaax4043
pubmed: 31579824
Neuropsychopharmacology. 2008 May;33(6):1391-401
pubmed: 17653109
Alcohol Clin Exp Res. 2018 Sep;42(9):1612-1622
pubmed: 29969156
Br J Addict. 1989 Nov;84(11):1353-7
pubmed: 2597811
Addict Biol. 2017 May;22(3):581-615
pubmed: 26833803
Neuropsychopharmacology. 2018 Dec;43(13):2532-2538
pubmed: 30093699
Handb Clin Neurol. 2014;125:355-68
pubmed: 25307585
Alcohol Clin Exp Res. 2019 May;43(5):907-915
pubmed: 30860603
Alcohol Clin Exp Res. 2014 Jan;38(1):78-89
pubmed: 23876228
Annu Rev Psychol. 2011;62:583-619
pubmed: 19575624
Alcohol Clin Exp Res. 2016 Sep;40(9):1865-73
pubmed: 27459715
J Abnorm Psychol. 2015 Nov;124(4):1050-63
pubmed: 26595481
Neuropsychopharmacology. 2018 Aug;43(9):1884-1890
pubmed: 29789576
Alcohol Clin Exp Res. 1997 Jun;21(4):613-9
pubmed: 9194913
Neuropsychopharmacology. 2017 Dec;42(13):2640-2653
pubmed: 28409564
Am J Psychiatry. 2017 Nov 1;174(11):1094-1101
pubmed: 28774194
Behav Res Ther. 2018 Feb;101:3-11
pubmed: 29110885
Addiction. 2014 Apr;109(4):585-95
pubmed: 24304235

Auteurs

Aaron C Lim (AC)

From the, Department of Psychology, (ACL, RG, ENG, AV, LRM, SD, EB, LAR), University of California, Los Angeles, Los Angeles, California, United States.

ReJoyce Green (R)

From the, Department of Psychology, (ACL, RG, ENG, AV, LRM, SD, EB, LAR), University of California, Los Angeles, Los Angeles, California, United States.

Erica N Grodin (EN)

From the, Department of Psychology, (ACL, RG, ENG, AV, LRM, SD, EB, LAR), University of California, Los Angeles, Los Angeles, California, United States.

Alexandra Venegas (A)

From the, Department of Psychology, (ACL, RG, ENG, AV, LRM, SD, EB, LAR), University of California, Los Angeles, Los Angeles, California, United States.

Lindsay R Meredith (LR)

From the, Department of Psychology, (ACL, RG, ENG, AV, LRM, SD, EB, LAR), University of California, Los Angeles, Los Angeles, California, United States.

Suzanna Donato (S)

From the, Department of Psychology, (ACL, RG, ENG, AV, LRM, SD, EB, LAR), University of California, Los Angeles, Los Angeles, California, United States.

Elizabeth Burnette (E)

From the, Department of Psychology, (ACL, RG, ENG, AV, LRM, SD, EB, LAR), University of California, Los Angeles, Los Angeles, California, United States.

Lara A Ray (LA)

From the, Department of Psychology, (ACL, RG, ENG, AV, LRM, SD, EB, LAR), University of California, Los Angeles, Los Angeles, California, United States.
Department of Psychiatry and Biobehavioral Sciences, (LAR), University of California, Los Angeles, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH